Scribd Logo
Upload

Welcome to Scribd!

  • HTA - SME - Case Study

    Uploaded by

    Geetika Sharma
    10 views2 pages
    This document provides a template for summarizing evidence for the drug Oxlumo's assessment by health technology assessment bodies in several countries. It includes a table to fill in with key details about each country's HTA process, focusing on reimbursement decision drivers, cost-effectiveness analysis submission requirements, and budget impact considerations. One-page summaries for each HTA body are to be provided with ratings of the drug's efficacy, safety, quality of life benefits, economic package, and overall evidence. Key takeaways from each assessment will also be included.

    Original Description:

    Case study

    Original Title

    HTA_SME_Case Study

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This document provides a template for summarizing evidence for the drug Oxlumo's assessment by health technology assessment bodies in several countries. It includes a table to fill in with key details about each country's HTA process, focusing on reimbursement decision drivers, cost-effectiveness analysis submission requirements, and budget impact considerations. One-page summaries for each HTA body are to be provided with ratings of the drug's efficacy, safety, quality of life benefits, economic package, and overall evidence. Key takeaways from each assessment will also be included.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    10 views2 pages

    HTA - SME - Case Study

    Uploaded by

    Geetika Sharma
    This document provides a template for summarizing evidence for the drug Oxlumo's assessment by health technology assessment bodies in several countries. It includes a table to fill in with key details about each country's HTA process, focusing on reimbursement decision drivers, cost-effectiveness analysis submission requirements, and budget impact considerations. One-page summaries for each HTA body are to be provided with ratings of the drug's efficacy, safety, quality of life benefits, economic package, and overall evidence. Key takeaways from each assessment will also be included.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    Prepare evidence summary for Oxlumo in UK (NICE), Spain (AEMPS), France (HAS), Germany (G-BA) Canada (CADTH) and

    Australia (PBAC) with Key Takeaways focused on decision drivers. One slide for each assessment

    DRUG Oxlumo (lumasiran) Decision date MA date

    HTA ASSESSMENT OUTCOME: Rating

    HAS Perception of Evidence


    Efficacy

    Safety

    QoL

    Economic Package

    Overall Evidence
    Package

    KEY TAKEAWAYS

    Provide source link in the footnotes


    1 © 2022 EVERSANA. All Rights Reserved. CONFIDENTIAL.
    Internal Use Only General and Administrative
    Please complete the below table to differentiate the countries based on archetype

    Country HTA body Key reimbursement decision driver CE analysis submitted CE threshold (cost/QALY) Mandatory budget impact
    Mention if it is Cost-
    Name of the HTA body effectiveness/Clinical Mention whether Y/N Mention whether Y/N Mention whether Y/N
    effectiveness/Budget impact driven
    Denmark
    France
    Germany
    Ireland
    Italy
    Netherlands
    Norway
    Scotland
    Spain
    Sweden
    United Kingdom
    S. Korea
    Canada
    Australia

    2 © 2022 EVERSANA. All Rights Reserved. CONFIDENTIAL.


    Internal Use Only General and Administrative

    You might also like